CryoPort, Inc. (NASDAQ:CYRX) Receives $18.00 Consensus PT from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

Several equities analysts have recently commented on CYRX shares. Guggenheim boosted their target price on shares of CryoPort from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, August 7th. KeyCorp raised their target price on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday, June 8th. Finally, Roth Capital reiterated a “buy” rating and issued a $21.00 price target on shares of CryoPort in a research note on Friday, August 7th.

Insider Transactions at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the sale, the chief executive officer directly owned 1,201,814 shares in the company, valued at approximately $17,919,046.74. The trade was a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the sale, the insider owned 109,719 shares in the company, valued at $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 256,441 shares of company stock valued at $4,051,923. 9.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of CryoPort by 305.0% in the second quarter. California State Teachers Retirement System now owns 10,707 shares of the company’s stock valued at $168,000 after purchasing an additional 8,063 shares in the last quarter. Highland Investment Advisors LLC bought a new stake in CryoPort in the second quarter worth $306,000. Kerrisdale Advisers LLC purchased a new stake in CryoPort during the second quarter valued at $355,000. Headlands Technologies LLC raised its stake in CryoPort by 14.5% during the second quarter. Headlands Technologies LLC now owns 38,742 shares of the company’s stock valued at $608,000 after purchasing an additional 4,906 shares in the last quarter. Finally, Wellington Management Group LLP bought a new position in CryoPort during the second quarter valued at $8,398,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Trading Down 0.9%

Shares of CYRX opened at $16.57 on Thursday. The business’s 50 day moving average is $15.62 and its 200 day moving average is $12.46. CryoPort has a 12-month low of $7.61 and a 12-month high of $17.20. The company has a market capitalization of $839.27 million, a PE ratio of -18.41 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.The business had revenue of $48.97 million during the quarter, compared to the consensus estimate of $48.18 million. Equities research analysts predict that CryoPort will post -0.83 earnings per share for the current year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.